| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Courses and Workshops |
|
|
| |
| |
| |
August 01, 2006 |
|
|
| |
|
|
| |
|
|
|
University of Oxford BioSciences, Oxford, UK
18 - 20 September 2006
This University of Oxford course is an introduction to modern developments in molecular biology and genetic engineering and a discussion of recent developments in the law of patents. The scientific sessions will consider DNA and its replication and expression in both bacteria and higher cells; regulation, differentiation and development; cloning; genetic libraries and screening techniques; and characterizing and altering cloned DNA. The legal sessions will focus on various aspects of patent law in the field of biotechnology, particularly following the judgment in the Kirin-Amgen v TKT case.Who is it for?
This course will be of particular interest to those working in the Intellectual Property departments of pharmaceutical and biotechnology companies; to patent agents and patent lawyers, both from the UK and from elsewhere in Europe; to research biologists with an interest in the legal consequences of developments in modern biology; and to those interested in financing and developing biotechnological industries.
|
|
|
|
|
|
|
|
Organized by:
|
|
University of Oxford BioSciences |
|
|
Invited Speakers:
|
|
Professor Michael Yudkin
Michael Yudkin is a University Lecturer in the University of Oxford’s Department of Biochemistry and Fellow of Kellogg College, with a particular interest in the transcriptional regulation of spore formation in Bacillus. Co-author of Comprehensible Biochemistry (Longman), Professor Yudkin was appointed by the House of Lords as their scientific advisor in the appeal in the Kirin-Amgen v TKT patent dispute involving erythropoietin. Gregor Grant
Gregor is a partner with Marks & Clerk Solicitors, a specialist patent and IP law practice. He was formerly senior partner of Needham & Grant, then Head of Intellectual Property with Wragge & Co LLP. He has spent most of his working life in patent litigation in many different technical areas. These include pharmaceuticals and biotechnology. He was heavily involved in the long-running Chiron litigation on patents for hepatitis C viral peptides, and advises biotech companies about patenting issues and strategies. Chris Norbury
Chris is Head of the Cell Cycle Group in the Imperial Cancer Research Fund Laboratories working in the University of Oxford's Institute of Molecular Medicine. Prior to this he carried out postdoctoral studies on eukaryotic cell cycle control in the Microbiology Unit at the University of Oxford under Professor Paul Nurse.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
n/a
|
|
|
|
|
|
|
|
Registration:
|
|
http://www.conted.ox.ac.uk/cpd/short_course_appform.pdf
|
|
|
E-mail:
|
|
cpdbio@conted.ox.ac.uk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|